IL17A and neoplasm: Taken together, the above clinical data suggest that expression of the IL-17A-IL-17RA/TL-17RC axis may modulate the progression of LUAD, especially in patients with high levels of tumor infiltrating lymphocytes and a high tumor mutation burden.